|
PHF16 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.08700048961907E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.19369999732555E-10 |
| Normal-vs-Stage2 |
8.195900E-04 |
| Normal-vs-Stage3 |
3.29499999995875E-06 |
| Normal-vs-Stage4 |
3.154000E-04 |
| Stage1-vs-Stage2 |
2.538800E-01 |
| Stage1-vs-Stage3 |
2.091600E-01 |
| Stage1-vs-Stage4 |
2.735600E-01 |
| Stage2-vs-Stage3 |
8.840400E-01 |
| Stage2-vs-Stage4 |
9.337000E-01 |
| Stage3-vs-Stage4 |
9.565200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.58219992663078E-10 |
| Normal-vs-AfricanAmerican |
9.174800E-04 |
| Normal-vs-Asian |
3.808000E-04 |
| Caucasian-vs-AfricanAmerican |
6.926600E-01 |
| Caucasian-vs-Asian |
1.208810E-01 |
| AfricanAmerican-vs-Asian |
1.481620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.59569999991227E-07 |
| Normal-vs-Female |
5.67230040715572E-10 |
| Male-vs-Female |
7.640800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.05170003209076E-09 |
| Normal-vs-Age(41-60Yrs) |
4.4767999995976E-07 |
| Normal-vs-Age(61-80Yrs) |
1.98688999999419E-05 |
| Normal-vs-Age(81-100Yrs) |
4.850400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.183830E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.283900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.156100E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.746400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.188000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.078600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.846400E-01 |
| Classical-VS-Follicular |
4.95649999998626E-06 |
| Classical-VS-Other |
4.795600E-01 |
| Classical-VS-Normal |
3.58812979328604E-12 |
| Tall-VS-Follicular |
6.039900E-03 |
| Tall-VS-Other |
6.644800E-01 |
| Tall-VS-Normal |
6.24120000000117E-05 |
| Follicular-VS-Other |
2.635000E-01 |
| Follicular-VS-Normal |
1.603750E-02 |
| Other-VS-Normal |
6.757500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.65839999999307E-06 |
| Normal-vs-N1 |
1.739460E-03 |
| N0-vs-N1 |
7.301600E-01 |
|
|
